ClinicalTrials.gg
CompletedNCT06522945Updated Jan 9, 2026

To Evaluate the Pharmacokinetics and Safety of TQD3524 for Injection in Renal Impairment Subjects

A Phase 1 interventional study of TQD3524 and TQD3524 in Multi-resistant Gram-negative Bacteria Cause Infection, sponsored by Chia Tai Tianqing Pharmaceutical Group Co., Ltd.. Completed at 1 site in China. Open to participants aged 18 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-01-09.

Sponsored by Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (part of Sino Biopharmaceutical Limited) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
48
Allocation
Non-randomized
Ages
18 Years to 75 Years
Sex
All
01

Study summary

This is an open, open-label, parallel, single-dose, phase I clinical study designed to evaluate the pharmacokinetic (PK) profile of TQD3524 injection in patients with renal impairment after a single dose, and to evaluate the urinary excretion of the drug in these patients after a single dose, as well as to evaluate the safety of the drug in these patients after a single dose.

02

Conditions studied

  • Multi-resistant Gram-negative Bacteria Cause Infection
03

In context

Lead sponsor

Chia Tai Tianqing Pharmaceutical Group Co., Ltd. is the lead sponsor of 320 studies on the registry; 76 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. All subjects are required to meet all of the following criteria for inclusion in this study:

    • Understand the content, process and possible adverse reactions of the trial, be able to complete the study in accordance with the requirements of the trial protocol, and voluntarily sign the ;
    • Participants (including their partners) voluntarily used effective within 6 months from screening until the last use of study drug;
    • Participants aged 18 \~ 75 ;
    • (BMI) and 18 or 32 kg/m2 or less, and the male weight 50 kg or greater, female weight 45 kg or more;
  2. For renal impairment subjects, also required meet all of the following criteria for inclusion in this study:

    • Subjects with moderate to severe renal insufficiency and end-stage renal disease were required to meet the diagnostic criteria for chronic kidney disease;
    • Stable renal function: creatinine detection of at least two intervals of 3 days (30 days before the screening test results for the first time acceptable) inside and outside school or in our test result, and two detecting serum creatinine results before and after the fluctuation (calculation formula: (second results - 1)) / 1 time is less than 30%;
    • During the screening period, the individual (GFR, mL/min, using the Modification of Diet in Renal Disease (MDRD) formula, based on the results of the second serum creatinine test) was classified as follows: 60≤GFR≤89 mL/min (Group A, mild renal dysfunction, chronic kidney disease stage 2 (CKD2) period), or 30≤GFR≤59 mL/min (Group B, moderate renal dysfunction, chronic kidney disease stage 3 (CKD3) period), or 15≤GFR≤29 mL/min (Group C, severe renal dysfunction, chronic kidney disease stage 4 (CKD4) period), or GFR\<15 mL/min (Group D, end-stage renal disease, not on dialysis; Group E, end-stage renal disease, on dialysis);
  3. For normal subjects, also required meet all of the following criteria for inclusion in this study:

    • During the screening period, normal vital signs, laboratory tests, physical examination, 12-lead , chest radiographs, and echocardiography results, or abnormal results determined by the investigator to be of no clinical significance, are considered normal.

Exclusion criteria

Exclusion Criteria:

  1. All subjects were not eligible for the study if they met any of the following criteria:

    • Individuals with an allergy disposition, or those with a history of allergic reactions to polymyxin-type drugs (including polymyxin B, polymyxin sulfate, and polymyxin E monosodium salt);
    • Participants who have had any type of treatment or untreated malignant tumor (excluding basal cell carcinoma of the skin) within the past 5 years or at baseline;
    • Participants who have had a serious digestive, respiratory, nervous, hematological, endocrine, tumor, immune, psychological, or cardiovascular disease within the past year and are deemed unfit for the study by the investigator;
    • Participants who have had a major illness or surgery within the past 4 weeks or plan to undergo surgery during the study period;
    • Participants who have donated blood (or lost blood) of at least 400 mL within the past 3 months or have received blood products;
    • Participants who have smoked an average of more than 10 cigarettes per day within the past 3 months;
    • Participants who have consumed an average of more than 14 units (female subjects) or 21 units (male subjects) of alcohol per week within the past 3 months (1 unit = 285 mL of beer, 25 mL of distilled spirits, or 100 mL of wine);
    • Participants who have consumed a special diet (including dragon fruit, mango, grapefruit, and/or xanthine diet, chocolate) and/or consumed excessive tea, coffee, grapefruit/grapefruit juice, and/or caffeine-containing beverages (an average of 8 cups or more per day, 200 mL per cup) within the past 2 weeks;
    • Participants who have consumed any alcoholic beverages within 48 hours of receiving the study drug or who have a positive breath alcohol test; 10) Individuals with a history of drug abuse within the past 5 years, or who have used soft drugs (e.g. marijuana) within the past 3 months, or who have used hard drugs within the past year, or who have a positive drug screen at baseline (if urine is available, screen for end-stage renal disease);
    • Individuals with positive antibody; positive virus (HCV) antibody or positive; positive syphilis treponemal antibody;
    • Pregnant or lactating women, and women of with a positive pregnancy test result;
    • Individuals who have used strong inhibitors or inducers of liver metabolizing enzymes within the past 14 days;
    • Other situations that the investigator considers inappropriate for enrollment.
  2. Renal impairment subjects were not eligible for the study if they met any of the following criteria:

    • With acute renal failure, has a history of renal transplantation, or expected during the test need a kidney transplant or accept any type of dialysis patients;
    • With obstructive urinary tract diseases (such as urinary tract obstruction caused by urinary calculi, abdominal space occupying lesions, etc.) or causes of renal damage unrelated to renal parenchymal dysfunction (such as polycystic kidney disease, renal tumor, renal artery stenosis, drugs, severe infection, hypovolemia, heart failure, etc.);
    • Patients with urinary incontinence;
    • Screening, treatment and/or other drug combined treatment of diseases have not meet a month stability, within a month or a new medication (except for temporary or intermittent use of drugs, such as a month use erythropoietin, or temporary require the use of diuretics, etc.);
    • Congestive heart failure of (NYHA) class III or IV, or \<50% at screening;
    • On the stage screening or baseline, systolic blood pressure 160 mmHg and 80 mmHg or less, or diastolic blood pressure 100 mmHg or 50 mmHg or less, or heart rate \< 50 times/min or > 100 times/min;
    • (ALT) or aspartate aminotransferase (AST) >2×Up Limit of Normal(), total >1.5×ULN; Albumin \< 25 g/L; \<1.0×109/L; \< 80 g/L; The count \< 75 x 109 / L; 2) Participants who were enrolled in another clinical trial and used any drug or medical device within 1 month before screening, based on the last investigational drug administration date (at least 5 half-lives between investigational drug administration and this study administration for long-half-life investigational drug);
  3. Normal subjects were excluded from the study if they met any of the following criteria:

    • Participants who were enrolled in other clinical trials and used any investigational drug or device within 3 months before screening, based on the date of last investigational drug administration (for investigational drug with long half-life, at least 5 half-life intervals between investigational drug administration and this study);
    • For 14 days before or within 5 half-life of longer (to) the use of any drugs.
Terms in these criteria, in plain language(18)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
48 participants (actual)

Study arms

  • Active comparator
    A: Mild Renal Impairment (GFR:60~89 mL/min)

    A: TQD3524 2.5 mg/kg administered as a 90 minute infusion via infusion pump, single dose

    Drug: TQD3524

  • Active comparator
    B: Moderate Renal Impairment (GFR:30~59 mL/min)

    B: TQD3524 2.5 mg/kg administered as a 90 minute infusion via infusion pump, single dose

    Drug: TQD3524

  • Active comparator
    C: Severe Renal Impairment (GFR:15~29 mL/min)

    C: TQD3524 1.25 mg/kg administered as a 90 minute infusion via infusion pump, single dose

    Drug: TQD3524

  • Active comparator
    D: End-stage renal disease (patients undialyzed ) (GFR<15 mL/min)

    D: TQD3524 1.25 mg/kg administered as a 90 minute infusion via infusion pump, single dose

    Drug: TQD3524

  • Active comparator
    E: End-stage renal disease (patients dialyzed) (GFR<15 mL/min)

    E: TQD3524 1.25 mg/kg administered as a 90 minute infusion via infusion pump, single dose

    Drug: TQD3524

  • Active comparator
    F: Normal (GFR≥90mL/min)

    F: TQD3524 2.5 mg/kg administered as a 90 minute infusion via infusion pump, single dose

    Drug: TQD3524

Interventions

  • DrugTQD3524

    Polymyxin antibiotics

  • DrugTQD3524

    Polymyxin antibiotics

  • DrugTQD3524

    Polymyxin antibiotics

  • DrugTQD3524

    Polymyxin antibiotics

  • DrugTQD3524

    Polymyxin antibiotics

  • DrugTQD3524

    Polymyxin antibiotics

06

What researchers measure

Primary outcomes

  1. Peak concentration (Cmax)

    Maximum plasma drug concentration

    Time frame: Before administration, 1.75 , 2 , 2 .5, 3.5, 5 , 7 , 9,12 , 16, 24 hours after administration

  2. Area under the concentration-time curve (AUC)

    Area under the plasma concentration-time curve

    Time frame: Before administration, 1.75 , 2 , 2 .5, 3.5, 5 , 7 , 9,12 , 16, 24 hours after administration

  3. Time-to-maximum concentration (Tmax)

    Time-to-maximum concentration

    Time frame: Before administration, 1.75 , 2 , 2 .5, 3.5, 5 , 7 , 9,12 , 16, 24 hours after administration

  4. Plasma half life (t1/2)

    The time it takes for the concentration or amount in the body of that drug to be reduced by exactly one-half

    Time frame: Before administration, 1.75 , 2 , 2 .5, 3.5, 5 , 7 , 9,12 , 16, 24 hours after administration

  5. Total body clearance (CLt)

    Total body clearance of TQD3524

    Time frame: Before administration, 1.75 , 2 , 2 .5, 3.5, 5 , 7 , 9,12 , 16, 24 hours after administration

  6. Renal clearance (CLr)

    Renal clearance of TQD3524

    Time frame: Before administration, 1.75 , 2 , 2 .5, 3.5, 5 , 7 , 9,12 , 16, 24 hours after administration

  7. Apparent volume of distribution (Vd/F)

    Volume of distribution based on the terminal phase

    Time frame: Before administration, 1.75 , 2 , 2 .5, 3.5, 5 , 7 , 9,12 , 16, 24 hours after administration

  8. Terminal elimination rate (λz)

    First-order rate constant associated with the terminal (log-linear) elimination phase

    Time frame: Before administration, 1.75 , 2 , 2 .5, 3.5, 5 , 7 , 9,12 , 16, 24 hours after administration

  9. Mean residence time (MRT)

    The average time that the drug stays in the body

    Time frame: Before administration, 1.75 , 2 , 2 .5, 3.5, 5 , 7 , 9,12 , 16, 24 hours after administration

Secondary outcomes

  1. Amount Excreted in Urine as Unchanged Drug or Metabolite (Ae0-24)

    Ae0-24 of TQD3524 and the active ingredients in urine

    Time frame: Before administration, 1.75 , 2 , 2 .5, 3.5, 5 , 7 , 9,12 , 16, 24 hours after administration

  2. Adverse event rate

    The occurrence of all adverse events (AEs), serious adverse events (SAEs) and treatment-related adverse events (TEAEs).

    Time frame: Baseline up to 72 hours

07

Study locations

1 site
  • The First Affiliated Hospital of Shandong First Medical University (Qianfoshan Hospital)
    Jinan, Shandong 250000, China
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jul 2024 to primary completion in Dec 2025, 16 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 23, 2024
First posted
Jul 26, 2024
StartActual
Jul 24, 2024
Primary completionActual
Dec 18, 2025
CompletionActual
Dec 18, 2025
Last update
Jan 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 9, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06522945
Responsible party
Sponsor
First posted
Jul 26, 2024
Start date
Jul 24, 2024
Primary completion
Dec 18, 2025
Completion
Dec 18, 2025
Last update
Jan 9, 2026

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion